Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APEX: Osimertinib + Carboplatin + Pemetrexed vs Amivantamab + Lazertinib in EGFR-Mutant Advanced NSCLC
jRCT1031260351Phase 3Recruiting
- Sponsor
- Japan Clinical Oncology Group
- Start
- Jul 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing Osimertinib + Carboplatin + Pemetrexed with Amivantamab + Lazertinib (2 arms). Primary endpoints: overall survival and progression-free survival. Started Jul 2026; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1031260351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260351.